Deadline extended! Apply now! Academy of Management #AOM2025

Grateful for the invitation to present our paper "Mind the Gap in Drug Development: Understanding the Whitespace Between Clinical Trials" at Program On Regulation, Therapeutics, And Law Guest Lecture Series hosted by @HarvardMed and Brigham and Women's Hospital. The insightful feedback was invaluable! Thanks for the

This podcast by NVIDIA highlights how big pharma like Bristol Myers Squibb is using #AI in their drug discovery and development. 𝑬𝒏𝒉𝒂𝒏𝒄𝒆𝒅 𝑯𝒚𝒑𝒐𝒕𝒉𝒆𝒔𝒊𝒔 𝑻𝒆𝒔𝒕𝒊𝒏𝒈: AI improves the quality of initial drug hypotheses, rapidly testing multiple scenarios simultaneously,

Another energizing and successful STR - Strategic Management Division PDW on Strategy and Innovation in the Biopharmaceutical and Healthcare sectors! Lamar Pierce set the tone with an inspiring discussion on the need for more research in these vital areas. Jillian Darroch Chown shared impactful insights

Connecting with friends from London Business School Strategy and Entrepreneurship PhD alumni at the Academy of Management in Copenhagen was a highlight of the conference. It was wonderful seeing Ahmadreza Mostajabi Aldona Kapacinskaite Divya Saxena Kevin Chuah Liinus Hietaniemi and Michael Blomfield! We

🎓 Call for Doctoral Consortium Participants: The 2025 West Coast Research Symposium (WCRS) on Technology Entrepreneurship will be hosted by the University of Washington in Seattle from September 11-12. The doctoral consortium will be held on the afternoon prior to the

Had the privilege of sharing my work today at U.S. FDA 's Economics Brown Bag with Jennifer Kao on how pharma firms adapt to GDPR. Key findings: 📉 Firms highly exposed to GDPR ran ~20% fewer clinical trials. 🎯 R&D scope narrowed: fewer patients, sites & disease areas. 🤝 Reliance

New essay on measuring biopharma innovation in Incidental Economist -- led by Sukhun Kang; I was happy to pitch in! theincidentaleconomist.com/wordpress/meas… TL;DR: We need broader/better definitions of innovation in drug dev.

A central question for us as strategy scholars—especially in critical fields like biopharma and healthcare—is how we translate rigorous research into real-world impact. How do we move beyond the pages of journals and influence the strategic decisions that shape the industry?

Our Haas School of Business case on Pinkfong & Baby Shark (aka the baby shark company!) is now available for general distribution and teaching! Thank you to my coauthor Sukhun Kang who deserves all the credit for making it happen! store.hbr.org/product/behind…